General Partner, Canaan Partners
Nina Kjellson is a General Partner at Canaan Partners. She has also been part of InterWest’s life sciences team since 2002, focusing on investments in health care.
She is a board member of Alvine Pharmaceuticals, Cebix, Eiger Biopharmaceuticals, Labrys, Lycera, Ocera, PrimeraDx, Trius Therapeutics (TSRX) , Welltok, and Xenon. Nina co-sponsored InterWest’s investments in TESARO and Sera Prognostics. She leads InterWest’s initiative in health care IT and is a director of the Consumer Medicine Summit, a forum to address the convergence of health care and consumer innovation. She serves as a mentor to the Nike+ Accelerator and to Blueprint Health.
Prior to joining InterWest, Nina was an investment manager at Bay City Capital, a life sciences merchant bank, and a research associate at Oracle Partners, a health care-focused hedge fund. Nina began her career conducting health policy and survey research with the Kaiser Family Foundation.
Nina received a B.A. in human biology from Stanford University.